Immix Biopharma Inc.
IMMX | NASDAQ
$7.20
-$0.77 (-9.66%)
At close: Nov 4, 2026, 4:00 PM ET
$7.27
+$0.07 (+0.97%)
After-hours:
Nov 5, 2026, 4:27 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -29.96M | -22.67M | -16.14M | -8.22M | -1.35M | -453.85K |
Interest Income | 555.53K | 1.02M | 572.01K | n/a | n/a | n/a |
Pretax Income | -29.4M | -21.66M | -15.57M | -8.22M | -24.38M | -1.13M |
Net Income | -29.44M | -21.61M | -15.43M | -8.23M | -24.38M | -1.15M |
Selling & General & Admin | 13.7M | 11.38M | 7.41M | 4.02M | 1.23M | 205.7K |
Research & Development | 16.26M | 11.29M | 8.74M | 4.2M | 126.53K | 248.15K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 29.96M | 22.67M | 16.14M | 8.22M | 1.35M | 453.85K |
Interest Expense | n/a | n/a | n/a | 497 | 179.85K | 101.98K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 29.96M | 22.67M | 16.14M | 8.22M | 1.35M | 453.85K |
Income Tax Expense | 37.72K | 41.04K | 26.42K | 10.27K | 6.01K | 17.55K |
Shares Outstanding (Basic) | 32.97M | 28.29M | 17.34M | 13.89M | 3.67M | 7.77M |
Shares Outstanding (Diluted) | 32.97M | 28.29M | 17.34M | 13.89M | 3.67M | 7.77M |
EPS (Basic) | -0.89 | -0.76 | -0.89 | -0.59 | -6.64 | -0.15 |
EPS (Diluted) | -0.89 | -0.76 | -0.89 | -0.59 | -6.64 | -0.15 |
EBITDA | -29.59M | -21.54M | -15.56M | -8.22M | -24.2M | -451.53K |
EBIT | -29.96M | -21.66M | -15.57M | -8.22M | -24.2M | -453.85K |
Depreciation & Amortization | 364.5K | 115.39K | 5.47K | 2.14K | 2.47K | 2.32K |
Add to Watchlist
Select watchlists to add or remove IMMX